Scalper1 News
Biotech stock Acorda Therapeutics (ACOR) soared 18% in early trading in the stock market today, a day after a court dismissed a patent challenge in a move that could have wider implications in the drug space. Late Monday, Acorda announced that the Patent Trials and Appeal Board (PTAB) had declined to institute the inter partes review (IPR) requested on two patents related to multiple-sclerosis drug Ampyra. The challenger was Kyle Bass, principal Scalper1 News
Scalper1 News